Aurobindo Pharma Ltd - Company Profile
Powered by 
All the data and insights you need on Aurobindo Pharma Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Aurobindo Pharma Ltd Strategy Report
- Understand Aurobindo Pharma Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Aurobindo Pharma Ltd (Aurobindo) is a vertically integrated pharmaceutical company that manufactures and markets generic pharmaceuticals and active pharmaceutical ingredients (APIs). Its product portfolio is spread across major therapeutic and product categories including antibiotics, anti-retroviral, systemic gastroenterological, central nervous system, cardiovascular, anti-allergies, anti-diabetics, other therapeutic areas. The company also produces novel proprietary biocatalysts, vitamins, minerals, dietary supplements, sports nutrition, functional foods, weight loss products and fermentation-based semi-synthetic products. Aurobindo operates manufacturing facilities in India, Brazil, Portugal and the US; and R&D facilities in India and the US. The company exports products to several countries worldwide. Aurobindo is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Plot no: 2, Maitrivihar, Ameerpet, Hyderabad, Telangana, 500038
Website
www.aurobindo.com
Telephone
91 40 66721200
No of Employees
15,690
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AUROPHARMA (NSE)
Revenue (2022)
$3.2B
6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-27.2%
(2022 vs 2021)
Market Cap*
$7.7B
Net Profit Margin (2022)
XYZ
-31.4%
(2022 vs 2021)
* As of and is in US$
Aurobindo Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Formulations: | Custom Synthesis |
| Antibacterials | Contract Services |
| Cardiovascular | API Development |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In April, the company commissioned four state-of-the-art manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products, and Granulation in Andhra Pradesh, India. |
| 2024 | Regulatory Approval | In February, the company received approval from the US Food and Drug Administration for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg. |
| 2023 | Contracts/Agreements | In March, the company along with Cipla and Viatris entered into sublicensing agreements with ViiV Healthcare and Medicines Patent Pool to produce generic forms of the long-acting cabotegravir used as pre-exposure prophylaxis for HIV. |
Competitor Comparison
| Key Parameters | Aurobindo Pharma Ltd | Viatris Inc | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | India | India | India |
| City | Hyderabad | Canonsburg | Mumbai | Hyderabad | Mumbai |
| State/Province | Telangana | Pennsylvania | Maharashtra | Telangana | Maharashtra |
| No. of Employees | 15,690 | 38,000 | 41,000 | 24,832 | 26,615 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mangalam Ramasubramanian Kumar | Chairman | Executive Board | 2024 | - |
| Kambam Nityananda Reddy | Vice Chairman; Managing Director | Executive Board | 2022 | - |
| Santhanam Subramanian | Chief Financial Officer | Senior Management | 2013 | - |
| Sanjay Chaturvedi | Chief Executive Officer - Apitoria Pharma Private Ltd | Senior Management | 2023 | - |
| Ch. Venkat Nageswar | Director - Apitoria Pharma Private Ltd | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward